These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22022197)

  • 1. Ovarian hyper-response to administration of an GnRH-agonist without gonadotropins.
    Park HT; Bae HS; Kim T; Kim SH
    J Korean Med Sci; 2011 Oct; 26(10):1394-6. PubMed ID: 22022197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian hyperstimulation following the sole administration of agonistic analogues of gonadotrophin releasing hormone.
    Weissman A; Barash A; Shapiro H; Casper RF
    Hum Reprod; 1998 Dec; 13(12):3421-4. PubMed ID: 9886527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
    J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which is the optimal timing for starting chemoprotection with gonadotropin-releasing hormone agonists after oocyte cryopreservation? Reflections on a critical case of ovarian hyperstimulation syndrome.
    Marin L; Vitagliano A; Capobianco G; Dessole F; Ambrosini G; Andrisani A
    J Gynecol Obstet Hum Reprod; 2021 Apr; 50(4):101815. PubMed ID: 32562778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study.
    Yılmaz N; Ceran MU; Ugurlu EN; Gülerman HC; Engin Ustun Y
    J Obstet Gynaecol; 2020 Aug; 40(6):837-842. PubMed ID: 31791167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between body mass index and oocyte maturation in patients triggered with GnRH agonist who are at high risk for severe ovarian hyperstimulation syndrome: an observational cohort study.
    Lainas GT; Lainas TG; Sfontouris IA; Venetis CA; Bosdou JK; Chatzimeletiou A; Grimbizis GF; Tarlatzis BC; Kolibianakis EM
    Reprod Biomed Online; 2020 Jan; 40(1):168-175. PubMed ID: 31839394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
    Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
    Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
    Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; Aboulfoutouh I; Khattab SM; van Wely M
    Cochrane Database Syst Rev; 2011 Jan; (1):CD008046. PubMed ID: 21249699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin-releasing hormone agonist and antagonists, on follicular fluid stem cell factor and serum urocortin 1 levels on the day of oocyte retrieval.
    Celik O; Celik E; Yilmaz E; Celik N; Turkcuoglu I; Ulas M; Kumbak B; Aktan E; Ozerol I
    Arch Gynecol Obstet; 2013 Dec; 288(6):1417-22. PubMed ID: 23801011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ovarian hyperstimulation induced by a GnRH agonist. About one case].
    Naifer R; Ajina M; Merdassi G; Bibi M; Ibala S; Saad A
    Gynecol Obstet Fertil; 2005 Dec; 33(12):994-7. PubMed ID: 16330236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard human chorionic gonadotropin versus double trigger for final oocyte maturation results in different granulosa cells gene expressions: a pilot study.
    Haas J; Ophir L; Barzilay E; Machtinger R; Yung Y; Orvieto R; Hourvitz A
    Fertil Steril; 2016 Sep; 106(3):653-659.e1. PubMed ID: 27341989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian hyperstimulation: effects of GnRH analogues. Does triggering ovulation with gonadotrophin-releasing hormone analogue prevent severe ovarian hyperstimulation syndrome?
    Casper RF
    Hum Reprod; 1996 Jun; 11(6):1144-6. PubMed ID: 8671408
    [No Abstract]   [Full Text] [Related]  

  • 20. Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem.
    Huber M; Hadziosmanovic N; Berglund L; Holte J
    Fertil Steril; 2013 Nov; 100(5):1270-6. PubMed ID: 23931964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.